|
1
|
Liu M, Wu M, Liu X, Zhou J, Lan Y, Zhang
H, Zhang X, Leng L, Zheng H and Li J: Assessing the quality of care
for skin malignant melanoma on a global, regional, and national
scale: A systematic analysis of the global burden of disease study
from 1990 to 2019. Arch Dermatol Res. 315:2893–2904. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arnold M, Singh D, Laversanne M, Vignat J,
Vaccarella S, Meheus F, Cust AE, de Vries E, Whiteman DC and Bray
F: Global burden of cutaneous melanoma in 2020 and projections to
2040. JAMA Dermatol. 158:495–503. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sarapultsev A, Gusev E, Komelkova M,
Utepova I, Luo S and Hu D: JAK-STAT signaling in inflammation and
stress-related diseases: Implications for therapeutic
interventions. Mol Biomed. 4:402023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q,
Bao Z, Lu J and Li L: Evolving cognition of the JAK-STAT signaling
pathway: autoimmune disorders and cancer. Signal Transduct Target
Ther. 8:2042023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang W, Lopez McDonald MC, Kim C, Ma M,
Pan ZT, Kaufmann C and Frank DA: The complementary roles of STAT3
and STAT1 in cancer biology: Insights into tumor pathogenesis and
therapeutic strategies. Front Immunol. 14:12658182023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang L, Chen J, Zhao Y, Gu L, Shao X, Li
J, Xu Y, Liu Z and Xu Q: Key candidate genes of STAT1 and CXCL10 in
melanoma identified by integrated bioinformatical analysis. IUBMB
Life. 71:1634–1644. 2019. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Isacescu E, Chiroi P, Zanoaga O, Nutu A,
Budisan L, Pirlog R, Atanasov AG and Berindan-Neagoe I: Melanoma
cellular signaling transduction pathways targeted by polyphenols
action mechanisms. Antioxidants (Basel). 12:4072023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao S, Wang S, Zhao Z, Zhang C, Liu Z, Ye
P, Xu Z, Yi B, Jiao K, Naik GA, et al: TUBB4A interacts with MYH9
to protect the nucleus during cell migration and promotes prostate
cancer via GSK3β/β-catenin signalling. Nat Commun. 13:27922022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanakkanthara A and Miller JH: βIII
tubulin overexpression in cancer: Causes, consequences, and
potential therapies. Biochim Biophys Acta Rev Cancer.
1876:1886072021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Novikov NM, Zolotaryova SY, Gautreau AM
and Denisov EV: Mutational drivers of cancer cell migration and
invasion. Br J Cancer. 124:102–114. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thomas SJ, Snowden JA, Zeidler MP and
Danson SJ: The role of JAK/STAT signalling in the pathogenesis,
prognosis and treatment of solid tumours. Br J Cancer. 113:365–371.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu X, Li J, Fu M, Zhao X and Wang W: The
JAK/STAT signaling pathway: From bench to clinic. Signal Transduct
Target Ther. 6:4022021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu Q, Bian Q, Rong D, Wang L, Song J,
Huang HS, Zeng J, Mei J and Wang PY: JAK/STAT pathway:
Extracellular signals, diseases, immunity, and therapeutic
regimens. Front Bioeng Biotechnol. 11:11107652023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gandalovicova A, Šůchová AM, Čermák V,
Merta L, Rösel D and Brábek J: Sustained inflammatory signalling
through Stat1/Stat2/IRF9 is associated with amoeboid phenotype of
melanoma cells. Cancers (Basel). 12:24502020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Osborn JL and Greer SF: Metastatic
melanoma cells evade immune detection by silencing STAT1. Int J Mol
Sci. 16:4343–4361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang W, Lopez McDonald MC, Hariprasad R,
Hamilton T and Frank DA: Oncogenic STAT transcription factors as
targets for cancer therapy: Innovative strategies and clinical
translation. Cancers (Basel). 16:13872024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Prutsch N, He S, Berezovskaya A, Durbin
AD, Dharia NV, Maher KA, Matthews JD, Hare L, Turner SD, Stegmaier
K, et al: STAT3 couples activated tyrosine kinase signaling to the
oncogenic core transcriptional regulatory circuitry of anaplastic
large cell lymphoma. Cell Rep Med. 5:1014722024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fu XQ, Liu B, Wang YP, Li JK, Zhu PL, Li
T, Tse KW, Chou JY, Yin CL, Bai JX, et al: Activation of STAT3 is a
key event in TLR4 signaling-mediated melanoma progression. Cell
Death Dis. 11:2462020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kortylewski M, Jove R and Yu H: Targeting
STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev.
24:315–327. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Kholina E, Szyk A, Fedorov VA,
Kovalenko I, Gudimchuk N and Roll-Mecak A: α-tubulin tail
modifications regulate microtubule stability through selective
effector recruitment, not changes in intrinsic polymer dynamics.
Dev Cell. 56:2016–2028.ed. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fu G, Yan S, Khoo CJ, Chao VC, Liu Z,
Mukhi M, Hervas R, Li XD and Ti SC: Integrated regulation of
tubulin tyrosination and microtubule stability by human
alpha-tubulin isotypes. Cell Rep. 42:1126532023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garcin C and Straube A: Microtubules in
cell migration. Essays Biochem. 63:509–520. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nami B and Wang Z: Genetics and expression
profile of the tubulin gene superfamily in breast cancer subtypes
and its relation to taxane resistance. Cancers (Basel). 10:2742018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song JX, Wang Y, Hua ZP, Huang Y, Hu LF,
Tian MR, Qiu L, Liu H and Zhang J: FATS inhibits the Wnt pathway
and induces apoptosis through degradation of MYH9 and enhances
sensitivity to paclitaxel in breast cancer. Cell Death Dis.
15:8352024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wagstaff W, Mwamba RN, Grullon K,
Armstrong M, Zhao P, Hendren-Santiago B, Qin KH, Li AJ, Hu DA,
Youssef A, et al: Melanoma: Molecular genetics, metastasis,
targeted therapies, immunotherapies, and therapeutic resistance.
Genes Dis. 9:1608–1623. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marconcini R, Pezzicoli G, Stucci LS,
Sergi MC, Lospalluti L, Porta C and Tucci M: Combination of
immunotherapy and other targeted therapies in advanced cutaneous
melanoma. Hum Vaccin Immunother. 18:19803152022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Papageorgiou C, Apalla Z, Manoli SM,
Lallas K, Vakirlis E and Lallas A: Melanoma: Staging and follow-up.
Dermatol Pract Concept. 11 (Suppl):e2021162S2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tolomeo M, Cavalli A and Cascio A: STAT1
and its crucial role in the control of viral infections. Int J Mol
Sci. 23:40952022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Niu M, Yi M, Dong B, Luo S and Wu K:
Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and
promotes the proliferation of colon cancer cells. Ann Transl Med.
8:9512020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li X, Wang F, Xu X, Zhang J and Xu G: The
dual role of STAT1 in ovarian cancer: Insight into molecular
mechanisms and application potentials. Front Cell Dev Biol.
9:6365952021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cerezo M, Guemiri R, Druillennec S,
Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C,
Agoussi S, et al: Translational control of tumor immune escape via
the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 24:1877–1886.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang J, Tan GL, Jiang M, Wang TS, Liu GH,
Xiong SS and Qing X: Effects of SENP1-induced deSUMOylation of
STAT1 on proliferation and invasion in nasopharyngeal carcinoma.
Cell Signal. 101:1105302023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wong GS, Lee JS, Park YY, Klein-Szanto AJ,
Waldron TJ, Cukierman E, Herlyn M, Gimotty P, Nakagawa H and Rustgi
AK: Periostin cooperates with mutant p53 to mediate invasion
through the induction of STAT1 signaling in the esophageal tumor
microenvironment. Oncogenesis. 2:e592013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang J, Ding Z, Luo Q and Xu W: Cancer
cell-derived exosomes promote cell proliferation and inhibit cell
apoptosis of both normal lung fibroblasts and non-small cell lung
cancer cell through delivering alpha-smooth muscle actin. Am J
Transl Res. 11:1711–1723. 2019.PubMed/NCBI
|
|
36
|
Xu J, Li Y and Hu H: Effects of lycopene
on ovarian cancer cell line SKOV3 in vitro: Suppressed
proliferation and enhanced apoptosis. Mol Cell Probes.
46:1014192019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ji Y, Yu M, Qi Z, Cui D, Xin G, Wang B,
Jia W and Chang L: Study on apoptosis effect of human breast cancer
cell MCF-7 induced by lycorine hydrochloride via death receptor
pathway. Saudi Pharm J. 25:633–637. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu G, Zhang Y, Li N, Zhang JB and Xu R:
LncRNA CCHE1 in the proliferation and apoptosis of gastric cancer
cells. Eur Rev Med Pharmacol Sci. 22:2631–2637. 2018.PubMed/NCBI
|
|
39
|
Tanaka A, Zhou Y, Ogawa M, Shia J,
Klimstra DS, Wang JY and Roehrl MH: STAT1 as a potential prognosis
marker for poor outcomes of early stage colorectal cancer with
microsatellite instability. PLoS One. 15:e02292522020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nivarthi H, Gordziel C, Themanns M, Kramer
N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knosel T, Kenner L,
et al: The ratio of STAT1 to STAT3 expression is a determinant of
colorectal cancer growth. Oncotarget. 7:51096–51106. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Legrier ME, Bièche I, Gaston J, Beurdeley
A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL,
Vacher S, et al: Activation of IFN/STAT1 signalling predicts
response to chemotherapy in oestrogen receptor-negative breast
cancer. Br J Cancer. 114:177–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wong GL, Manore SG, Doheny DL and Lo HW:
STAT family of transcription factors in breast cancer: Pathogenesis
and therapeutic opportunities and challenges. Semin Cancer Biol.
86:84–106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wudtiwai B, Makeudom A, Krisanaprakornkit
S, Pothacharoen P and Kongtawelert P: Anticancer activities of
hesperidin via suppression of up-regulated programmed death-ligand
1 expression in oral cancer cells. Molecules. 6:53452021.
View Article : Google Scholar
|
|
44
|
Okita R, Shimizu K, Nojima Y, Saisho S and
Nakata M: Tofacitinib overcomes an IFNγ-induced decrease in NK
cell-mediated cytotoxicity via the regulation of immune-related
molecules in LC-2/ad. Thorac Cancer. 12:775–782. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Breitenecker K, Homolya M, Luca AC, Lang
V, Trenk C, Petroczi G, Mohrherr J, Horvath J, Moritsch S, Haas L,
et al: Down-regulation of A20 promotes immune escape of lung
adenocarcinomas. Sci Transl Med. 13:eabc39112021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang J, Wang X, Huang B, Liu R, Xiong H,
Ye F, Zeng C, Fu X and Li L: An IFNγ/STAT1/JMJD3 axis 2021induces
ZEB1 expression and promotes aggressiveness in lung adenocarcinoma.
Mol Cancer Res. 19:1234–1246. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hashimoto K, Nishimura S, Ito T, Kakinoki
R and Akagi M: Immunohistochemical expression and
clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and
MAGE-A4 expression in highly aggressive soft tissue sarcomas. Eur J
Histochem. 66:33932022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sase S, Almad AA, Boecker CA, Guedes-Dias
P, Li JJ, Takanohashi A, Patel A, McCaffrey T, Patel H,
Sirdeshpande D, et al: TUBB4A mutations result in both glial and
neuronal degeneration in an H-ABC leukodystrophy mouse model.
Elife. 9:e529862020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sobierajska K, Ciszewski WM, Wawro ME,
Wieczorek-Szukala K, Boncela J, Papiewska-Pajak I, Niewiarowska J
and Kowalska MA: TUBB4B downregulation is critical for increasing
migration of metastatic colon cancer cells. Cells. 8:8102019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vemu A, Atherton J, Spector JO, Moores CA
and Roll-Mecak A: Tubulin isoform composition tunes microtubule
dynamics. Mol Biol Cell. 28:3564–3572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Du W and Elemento O: Cancer systems
biology: Embracing complexity to develop better anticancer
therapeutic strategies. Oncogene. 34:3215–3225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Afrang N and Honardoost M: Cell cycle
regulatory markers in melanoma: New strategies in diagnosis and
treatment. Med J Islam Repub Iran. 33:962019.PubMed/NCBI
|
|
53
|
Becker TM, Boyd SC, Mijatov B,
Gowrishankar K, Snoyman S, Pupo GM, Scolyer RA, Mann GJ, Kefford
RF, Zhang XD and Rizos H: Mutant B-RAF-Mcl-1 survival signaling
depends on the STAT3 transcription factor. Oncogene. 33:1158–1166.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Picco ME, Castro MV, Quezada MJ, Barbero
G, Villanueva MB, Fernández NB, Kim H and Lopez-Bergami P: STAT3
enhances the constitutive activity of AGC kinases in melanoma by
transactivating PDK1. Cell Biosci. 9:32019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Regis G, Pensa S, Boselli D, Novelli F and
Poli V: Ups and downs: The STAT1:STAT3 seesaw of Interferon and
gp130 receptor signalling. Semin Cell Dev Biol. 19:351–359. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kortylewski M, Komyod W, Kauffmann ME,
Bosserhoff A, Heinrich PC and Behrmann I: Interferon-gamma-mediated
growth regulation of melanoma cells: Involvement of STAT1-dependent
and STAT1-independent signals. J Invest Dermatol. 122:414–422.
2004. View Article : Google Scholar : PubMed/NCBI
|
